^
Association details:
| Biomarker: | MSI-H/dMMR + HLA-DPB1 overexpression |
|---|---|
| Cancer: | Colorectal Cancer |
| Drug: | Keytruda (pembrolizumab) (PD1 inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergistic effects of alpelisib (PI3K inhibitor) and ribociclib (CDK4/6 inhibitor) combination in preclinical colorectal cancer models.
Published date:
01/17/2023
Excerpt:
We identified 1549 patients with dMMR/MSI-H CRC; 242 patients of these had received pembrolizumab or nivolumab….High expression of HLA genes (HLA-DRB1, HLA-B, HLA-DQB1, HLA-DPB1, HLA-DPA1- p<0.02; fold change 2.1-3) was found in the good responder group...patients in the highest quartile of expression for either CD74, HLA-DQA1, HLA-DQB1, HLA-DPB1 or HLA-DRB1 had improved survival when compared to lower expressors (p< 0.05).
DOI:
10.1200/JCO.2023.41.3_suppl.167
